Human respiratory syncytial virus B cDNA and Antigen

Human respiratory syncytial virus type B (RSV-B) is a subtype of the human respiratory syncytial virus (RSV), which is a common cause of respiratory infections in humans, especially in young children and elderly individuals. RSV-B is one of the two major subtypes of RSV, the other being RSV-A, and is known to cause more severe illness compared to RSV-A. RSV-B is a highly contagious virus and spreads easily through respiratory droplets. The virus primarily infects the lower respiratory tract, causing symptoms such as coughing, wheezing, shortness of breath, and fever. RSV-B is a significant public health problem and its management and control is important for reducing the burden of respiratory illness worldwide.

An antigen is a substance that the immune system recognizes and reacts against. In the context of human respiratory syncytial virus type B (RSV-B), an RSV-B antigen can refer to any part of the virus that triggers an immune response, such as viral proteins or viral particles. RSV-B antigens can be used in the development of diagnostic tests for RSV-B infection, such as serologic assays or rapid antigen tests. RSV-B antigens can also be used in the development of vaccines for RSV-B, as they stimulate the immune system to produce protective antibodies against the virus.

The RSV-B genome is a single-stranded RNA molecule that encodes the information necessary for the virus to replicate and produce new viral particles. The RSV-B genome is organized into 10 genes that encode different viral proteins, including structural proteins that form the viral capsid and envelope, as well as non-structural proteins that regulate viral replication and evade the host immune response. Understanding the RSV-B genome and its organization is important for developing effective diagnostic tests and vaccines against RSV-B infection.

The matrix protein of Human Respiratory Syncytial Virus B (RSV B) is a key structural protein that plays a crucial role in the assembly and budding of the virus. The matrix protein forms a shell around the viral RNA genome and serves as a bridge between the viral envelope and the nucleocapsid. It is essential for the formation of viral particles and for the release of mature virions from infected cells.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E.coli expression Vector), which are ready for production of the recombinant proteins.